Exclusive Summary

• - Once-daily SR capsules with 25/100/200 mg strengths cover titration and maintenance needs for epilepsy and migraine prevention.
• - ~50 million epilepsy patients and ~1 billion with migraine globally, with 10–20% needing prophylaxis; ER/SR penetration remains low in many markets, offering first-to-market opportunities.
• - IR patents expired long ago, while ER/XR patents in some countries open in the late 2020s or have just started allowing generics, enabling differentiated distribution.
• - Versus brand XR, generics typically deliver 60–90% price cuts, and once-daily dosing improves adherence and persistence, boosting payer and channel acceptance.
• - ICH CTD dossier with feasible bioequivalence and stability across climate zones supports multi-region registration and distribution (MENA/LATAM/APAC).